Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes

Summary

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction that occurs following exposure to unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH).HIT with thrombosis (HITT) can cause devastating venous thromboembolism or arterial clots, prolonged hospitalization, and increased costs. To explore the economic and clinical implications of HIT and HITT, we initiated a single-center patient registry. In this report, we describe patient characteristics, comorbidities, management strategies, clinical outcomes, and costs. We enrolled 349 hospitalized patients with an enzyme immunoassay-confirmed diagnosis of HIT over a 40-month period. Patients were assessed for the primary outcome of 30-day mortality, as well as baseline characteristics, development of thrombosis, and the economic impact of HIT. The primary outcome measure was 30-day mortality and occurred in 58 (16.6%) patients, 40 (15.3%) in the HIT group versus 18 (20.7%) in the HITT group (p=0.25).The frequency of HIT was greater in patients exposed to UFH than in patients exposed to LMWH (0.8% vs. 0.2%, respectively, p<0.001). Both HIT and HITT patients who were exposed to UFH had higher hospital costs than those exposed to LMWH ($113,100 vs. $56,352, respectively, p<0.001). HIT remains an important clinical problem with a high mortality rate and significant cost, regardless of development of thrombosis. Prospective controlled trials need to be conducted to determine the optimal strategy to reduce the frequency of HIT.

Keywords

Heparin - heparin-induced thrombocytopenia - thrombosis

• References

• 1 Arepally GE, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
• 2 Warkentin TE, Greinacher A, Koster A. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
• 3 Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127: 35S-45S.
• 4 Kelton JG. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 2005; 127 (Suppl) 9S-20S.
• 5 Greinacher A, Farner B, Kroll H. et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
• 6 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metaanalysis. Blood 2005; 106: 2710-2715.
• 7 Morris TA, Castrejon S, Devendra G. et al. No difference in risk for thrombocytopenia during treatment of pulmonary embolism with deep vein thrombosis with either low molecular weight heparin or Unfractionated heparin. A metaanalysis. Chest 2007; 132: 1131-1139.
• 8 Warkentin TE, Greinacher A. So, does low-molecular-weight heparin cause less heparin-Induced thrombocytopenia than unfractionated heparin or not?. Chest 2007; 132: 1108-1110.
• 9 Levine RL, McCollum D, Hursting MJ. How frequently is venous thromboembolism in heparin -treated patients associated with heparin induced thrombocytopenia. Chest 2006; 130: 681-687.
• 10 National Consensus Standards for Prevention and Care of Venous Thromboembolism (VTE). http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/VTE.htm Accessed November 7, 2007.
• 11 Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131: 1644-1649.
• 12 Creekmore FM, Oderda GM, Pendleton RC. et al. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26: 1438-1445.
• 13 Warkentin TE, Sheppard J-AI, Moore JC. et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005; 146: 341-346.
• 14 Gocke J. Lower extremity venous ultrasonography. In: Essentials of vascular laboratory diagnosis. Blackwell Publishing; 2005: 184-206.
• 15 bThe PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990; 263: 2753-2759.
• 16 Schoepf UJ, Goldhaber SZ, Costello P. Spiral computed tomography for acute pulmonary embolism. Circulation 2004; 109: 2160-2167.
• 17 Stein PD, Athanasoulis C, Alavi A. et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation 1992; 85: 462-468.
• 18 Oliveira GB, Crespo EM, Becker RC. et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168: 94-102.
• 19 Foo S, Everett B, Yeh R. et al. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J 2006; 152: e1-7.
• 20 Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 2007; 120 (Suppl. 02) S137-S140.
• 21 Greinacher A. Too many hits in HIT?. Am J Hematol 2007; 82: 1035-1036.
• 22 Warkentin TE. et al. Heparin induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126: 311S-337S.
• 23 Pouplard C, Gueret P, Fouassier M. et al. Prospective evaluation of the _4Ts_ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 05: 1373-1379.
• 24 Lo G, Sigouin CS, Warkentin TE. What is the potential of overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007; 82: 1037-1043.
• 25 McGarry LJ, Thompson D, Weinstein MC. et al. Cost-effectiveness of thromboprophylaxis with a lowmolecular-weight heparin versus unfractionated heparin in acutely ill medical patients. Am J Managed Care 2004; 10: 632-642.